Cholinomimetic Agents

Overview

Cholinomimetic agents, also known as cholinergic agonists, are a class of drugs that mimic or enhance the effects of acetylcholine, the primary neurotransmitter of the parasympathetic nervous system. These agents stimulate or activate cholinergic receptors, leading to increased cholinergic activity in the body.

Cholinergic receptors are classified into two main types: nicotinic receptors and muscarinic receptors. Nicotinic receptors are found in the central and peripheral nervous systems, as well as on skeletal muscle cells, while muscarinic receptors are predominantly located in various organs and tissues throughout the body.

Cholinomimetic agents can have broad physiological effects due to the widespread distribution of cholinergic receptors. Here are some key applications and examples of cholinomimetic agents:

1. Ophthalmology:
   • Pilocarpine: Used to constrict the pupil (miosis) and reduce intraocular pressure in conditions such as glaucoma.
   • Carbachol: Similar to pilocarpine, used in glaucoma treatment to lower intraocular pressure.
2. Gastrointestinal Disorders:
   • Bethanechol: Used to stimulate smooth muscle contractions in the gastrointestinal tract and bladder, promoting gastrointestinal motility and treating conditions like postoperative ileus and urinary retention.
   • Neostigmine: Used to increase muscle tone and improve gastrointestinal motility in conditions such as paralytic ileus.
3. Alzheimer’s Disease:
   • Cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine): These drugs inhibit the breakdown of acetylcholine by the enzyme acetylcholinesterase, thereby increasing cholinergic activity in the brain. They are used to manage symptoms of Alzheimer’s disease and improve cognitive function.
4. Myasthenia Gravis:
   • Pyridostigmine: Used to improve muscle strength and treat muscle weakness in patients with myasthenia gravis, a neuromuscular disorder characterized by impaired neuromuscular transmission.
5. Neuromuscular Blockade Reversal:
   • Neostigmine and Edrophonium: These cholinesterase inhibitors are used to reverse neuromuscular blockade caused by non-depolarizing neuromuscular blocking agents, allowing for the restoration of muscle strength after surgical procedures.

It is important to note that cholinomimetic agents can have side effects due to their widespread effects on cholinergic receptors. These side effects may include increased salivation, sweating, gastrointestinal disturbances, bradycardia, and bronchoconstriction.

Cholinomimetic agents should be used with caution in patients with certain medical conditions such as asthma, peptic ulcers, urinary obstruction, or bradycardia. They should also be used under the guidance of a healthcare professional to ensure proper dosing and monitoring.

As always, it is important to consult a healthcare professional for accurate information and guidance regarding the use of cholinomimetic agents or any other medications.

Direct agonists

• Most direct agonists are resistant to acetylcholinesterase (AChE)  
  • thereby prevents breakdown of agonist
  • increases cholinergic effect

Direct Agonists	Uses	Mechanism of Action
Methacholine	• Challenge test for bronchial airway hyperactivity/asthma	• Rapid onset of contraction of smooth muscles in the airways and increases tracheobronchial secretions • Slightly resistant to acetylcholine-esterase (AChE)
Pilocarpine	• Management of glaucoma	• Contracts the pupillary sphincter (miosis) and ciliary muscle (improved accommodation) • Lowers intraocular pressure by reducing resistance to aqueous humor outflow • Resistant to AChE
Bethanechol	• Acute postoperative and postpartum urinary retention • Neurogenic ileus	• Causes bladder contractions which initiates urination • stimulates gastric motility and tone restoring peristalsis • Resistant to AChE
Carbachol	• Lowers intraocular pressure treating glaucoma • Pupillary contraction	• Stimulates muscarinic receptors causing miosis  • Resistant to AChE

Indirect Agonists (Cholinesterase Inhibitors)

• Mechanism of action
  • all work by inhibiting ACHE 
  • thereby preventing the degradation of ACH prolonging its effects

Indirect Agonist	Uses	Notes
Physostigmine	• Glaucoma • Atropine overdose or Atropa belladonna (deadly nightshade) ingestion	• CNS penetration • Absorbs well on all bodily surfaces
Neostigmine	• Postoperative and neurogenic ileus and urinary retention • Myasthenia gravis • Reversal of neuromuscular junction blockade (postoperative)	• No CNS penetration
Pyridostigmine	• Myasthenia gravis	• No CNS penetration
Edrophonium	• Diagnosis of myasthenia gravis  • Ileus • Arrhythmias	• Extremely short lived (5 – 15 min)
Echothiophate	• Glaucoma	• Long-lasting (100 hours) • No CNS penetration • Insecticides: malathion is safe in humans but parathion is harmful and both can penetrate the CNS

Cholinesterase Inhibitor Poisoning

• Cholinesterase poisoning symptoms
  • due to ingestion of parathion or cholinesterase inhibitors
  • symptoms result from the overstimulation of systemic cholinergic receptors
    • Glands: sweating, salivation, and lacrimation
    • GI and GU: diarrhea, abdominal cramping, urination
    • Heart: bradycardia
    • Respiratory: bronchospasm
    • Musculoskeletal: skeletal muscle overexcitation
    • Eye: miosis
  • Mnemonic: Diarrhea, Urination, Miosis, Bradycardia, Emesis, Lacrimation, Lethargy, and Salivation
• Treatment
  • atropine: blocks muscarinic receptors
  • pralidoxime: regenerated AChE

Studies of Cholinomimetic Agents

Numerous studies have been conducted on cholinomimetic agents to evaluate their efficacy, safety, and potential applications. Here are a few notable studies on cholinomimetic agents:

1. Cholinesterase Inhibitors in Alzheimer’s Disease:
   • The AD2000 Collaborative Group conducted a study published in The Lancet that evaluated the effectiveness of cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) in the treatment of Alzheimer’s disease. The study demonstrated that these agents provided modest cognitive and global benefits compared to placebo.
   • A meta-analysis published in the Cochrane Database of Systematic Reviews reviewed multiple trials and concluded that cholinesterase inhibitors had beneficial effects on cognitive function, global function, and activities of daily living in patients with mild to moderate Alzheimer’s disease.
2. Cholinomimetics in Myasthenia Gravis:
   • A study published in JAMA Neurology compared the effectiveness of different cholinesterase inhibitors (pyridostigmine, neostigmine, and ambenonium) in the treatment of myasthenia gravis. The findings showed that pyridostigmine was the most effective agent in improving muscle strength.
   • Another study published in Annals of Internal Medicine assessed the long-term efficacy and safety of pyridostigmine in myasthenia gravis patients. It demonstrated that pyridostigmine effectively maintained muscle strength over time with a favorable safety profile.
3. Cholinergic Agonists in Glaucoma:
   • A randomized controlled trial published in JAMA Ophthalmology compared the efficacy of cholinergic agonists (pilocarpine, carbachol) with prostaglandin analogs in the treatment of primary open-angle glaucoma. The study found that prostaglandin analogs were more effective in lowering intraocular pressure compared to cholinergic agonists.
   • A review article published in Ophthalmology provided an overview of various studies evaluating the use of cholinergic agonists in the treatment of glaucoma. It highlighted the role of cholinergic agents as adjunctive therapy and their effectiveness in reducing intraocular pressure.
4. Cholinomimetics in Postoperative Ileus:
   • A systematic review and meta-analysis published in Annals of Surgery examined the efficacy of cholinergic agents (bethanechol and neostigmine) in the treatment of postoperative ileus. The analysis showed that these agents significantly reduced the time to recovery of gastrointestinal function after surgery.
5. Cholinesterase Inhibitors in Lewy Body Dementia:
   • A study published in The New England Journal of Medicine investigated the effects of cholinesterase inhibitors (rivastigmine, donepezil) on cognitive impairment and neuropsychiatric symptoms in patients with dementia with Lewy bodies. The results demonstrated that cholinesterase inhibitors provided cognitive and behavioral benefits compared to placebo.

Check out Interview Preparation, CV and Personal Statement Editing – The Finale.